DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Thrombocytopenia - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Thrombocytopenia (98)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include thrombocytopenia. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 98   Next >>

Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Doxorubicin HCL
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Rituximab
    Dosage: maintenance

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Rituximab
    Dosage: maintenance

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-27

Patient:

Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Epirubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone and Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-20

Patient:

Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 375 mg/m2 on day 1 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: 100 mg on days 1-5 for chop and r-chop
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in

Reported by a physician from United States on 2012-07-06

Patient:

Reactions: Stomatitis, Hepatic Failure, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Haematotoxicity, Cardiac Disorder, Neutropenia, Thrombocytopenia, Renal Failure Acute

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Neulasta
    Dosage: on day 2 of a 14 day cycle
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: day 1-5
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 2 mg max
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxil
    Dosage: cohort 1: 20 mg/m2 cohort ii: 25 mg/m2 cohort iii: 30 mg/m2
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in female

Reported by a physician from Germany on 2012-07-06

Patient: female

Reactions: Presyncope, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Rituxan
    Dosage: 742.5 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Prednisolone
    Dosage: 100 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Cyclophosphamide
    Dosage: 1483 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Dosage: 100 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Vincristine
    Dosage: 3.94 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Ramipril; Nebivolol; Tiotropium Bromide; Levothyroxine Sodium; Trimethoprim + Sulfamethoxazole; Acyclovir; Simvastatin; Torsemide; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Pantoprazole



Possible Vincristine side effects in

Reported by a physician from South Africa on 2012-07-05

Patient:

Reactions: Pneumonia, Hepatotoxicity, Anaemia, Tuberculosis, Hyponatraemia, Kaposi's Sarcoma, Thrombocytopenia, Generalised Oedema

Drug(s) suspected as cause:
Lamivudine Stavudine Nevirapine
    Indication: Kaposi's Sarcoma AIDS Related

Vincristine
    Dosage: capped at 2 mg
    Indication: Kaposi's Sarcoma AIDS Related

Doxorubicin HCL
    Indication: Kaposi's Sarcoma AIDS Related

Etoposide
    Dosage: 50-100 mg for 1-21 days of a 28 day cycle.
    Administration route: Oral
    Indication: Kaposi's Sarcoma AIDS Related

Bleomycin Sulfate
    Dosage: 10 u/m2
    Indication: Kaposi's Sarcoma AIDS Related



Possible Vincristine side effects in 67 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: 67 year old male

Reactions: Weight Decreased, Anaemia, Acute Phosphate Nephropathy, Mental Status Changes, Hypercalcaemia, Hyperuricaemia, Haemodialysis, Tumour Lysis Syndrome, Renal Impairment, Oliguria, Leukocytosis, Thrombocytopenia, Decreased Appetite, Renal Failure Acute, Hepatosplenomegaly

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Chemotherapy

Vincristine
    Indication: Chemotherapy

Dexamethasone Sodium Phosphate
    Indication: Chemotherapy

Cyclophosphamide
    Indication: Chemotherapy



Possible Vincristine side effects in female

Reported by a physician from Germany on 2012-06-28

Patient: female

Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Neulasta
    Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Prednisolone
    Dosage: frequency 1 times in 2 week for 5 days
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole



Possible Vincristine side effects in

Reported by a physician from France on 2012-06-27

Patient:

Reactions: Febrile Neutropenia, Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma, Thrombocytopenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Rituximab
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Granulocyte Colony Stimulating Factor
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Dosage: on days 1-5, every 21 days for 6 cycles
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a individual with unspecified qualification from Korea, Republic of on 2012-06-26

Patient:

Reactions: Abdominal Pain, Hyperbilirubinaemia, Anaemia, Alanine Aminotransferase Increased, Febrile Neutropenia, Rash, Pyrexia, Peripheral Sensory Neuropathy, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Asthenia, Thrombocytopenia

Drug(s) suspected as cause:
Vincristine
    Dosage: given on day 1 of every cycle; dose: 1.4 mg/m2 ( maximum 2.0 mg)
    Indication: B-Cell Lymphoma

Prednisolone
    Dosage: given on days 1 to 5 of every cycle (repeated every 3 weeks)
    Administration route: Oral
    Indication: B-Cell Lymphoma

Mabthera
    Dosage: on day 1 of every cycle
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: given on day 1 of each cycle
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-22

Patient:

Reactions: Performance Status Decreased, Pain, Abdominal Pain Upper, Fatigue, Neutropenic Infection, Thrombocytopenia, Hallucination, Dyspnoea, Vomiting, Nausea, Hyperglycaemia, Haemoglobin Abnormal, Pancytopenia, Febrile Neutropenia, Toxicity To Various Agents, Haemoglobin, Neutropenia, Diffuse Large B-Cell Lymphoma, Cardiovascular Disorder, Leukopenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Vincristine
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Granulocyte Macrophage Colony Stim Factor
    Dosage: days 3-10
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Anti-Emetics; Dapsone; Trimethoprim + Sulfamethoxazole



Possible Vincristine side effects in male

Reported by a physician from Italy on 2012-06-14

Patient: male

Reactions: Epstein-Barr Virus Infection, Anaemia, Cytomegalovirus Infection, Neutropenia, Thrombocytopenia, Disease Progression, Infection

Drug(s) suspected as cause:
Carmustine
    Indication: Burkitt's Lymphoma

Carboplatin
    Indication: Burkitt's Lymphoma

Rituximab
    Indication: Burkitt's Lymphoma

Etoposide
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma

Melphalan Hydrochloride
    Indication: Burkitt's Lymphoma

Radiotherapy
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Cisplatin
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Ifosfamide
    Indication: Burkitt's Lymphoma

Granulocyte Colony Stimulating Factor
    Indication: Burkitt's Lymphoma

Methylprednisolone
    Indication: Burkitt's Lymphoma

Unknown Medication
    Dosage: antimicrobial prophylaxis
    Indication: Burkitt's Lymphoma

Other drugs received by patient: Unknown Medication



Possible Vincristine side effects in

Reported by a individual with unspecified qualification from United States on 2012-06-11

Patient:

Reactions: Nausea, Bacteraemia, Anaemia, Hypoalbuminaemia, Abscess, Neutropenia, Thrombocytopenia, Decreased Appetite

Drug(s) suspected as cause:
Azacitidine

Cyclophosphamide
    Dosage: for 6 to 9 days
    Indication: Lymphoma

Vincristine
    Dosage: for 8 days
    Indication: Lymphoma

Mabthera
    Dosage: for 8 days
    Indication: Lymphoma

Azacitidine
    Indication: Lymphoma



Possible Vincristine side effects in female

Reported by a physician from Germany on 2012-06-07

Patient: female

Reactions: Syncope, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1483 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Vincristine
    Dosage: 3.94 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Rituximab
    Dosage: 742.5 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Prednisolone
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Doxorubicin HCL
    Dosage: 100 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Acetylsalicylic Acid SRT; Simvastatin; Acyclovir; Nebivolol; Pantoprazole; Torsemide; Levothyroxine Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Enoxaparin Sodium; Ramipril



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-05

Patient: male, weighing 102.6 kg (225.7 pounds)

Reactions: Cardio-Respiratory Arrest, Respiratory Failure, Anaemia, Troponin I Increased, Thrombocytopenia, Infection

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Methotrexate
    Dosage: 1600 mg, cyclic
    End date: 2011-07-28

Adriamycin PFS
    Dosage: 101 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-05
    End date: 2011-07-05

Rituximab
    Dosage: 750 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-01
    End date: 2011-07-26

Methotrexate
    Dosage: 400 mg, cyclic
    Indication: Mantle Cell Lymphoma
    End date: 2011-07-27

Cytarabine
    Dosage: 6 g, cyclic
    Indication: Mantle Cell Lymphoma
    End date: 2011-07-30

Dexamethasone
    Dosage: 40 mg, cyclic
    Indication: Mantle Cell Lymphoma

Dexamethasone
    Dosage: 20 unk, unk
    Administration route: Oral
    End date: 2011-07-15

Vincristine
    Dosage: 2 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-05
    End date: 2011-07-12

Velcade
    Dosage: 2.6 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-01
    End date: 2011-07-26

Cyclophosphamide
    Dosage: 603 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-02
    End date: 2011-07-04

Other drugs received by patient: Filgrastim; Ferrous Sulfate TAB; Heparin; Senokot; Triamcinolone Acetonide; Compazine; Ciprofloxacin; Fluconazole; Omeprazole; Mesna; Prevident; Valtrex; Vitamin C / 00008001 /; Methylprednisolone; Periogard; Ultram; Vitamin D



Possible Vincristine side effects in female

Reported by a physician from Germany on 2012-06-04

Patient: female

Reactions: Syncope, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1483 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Dosage: 100 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisolone
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Vincristine
    Dosage: 3.94 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Rituximab
    Dosage: 742.5 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Other drugs received by patient: Nebivolol; Torsemide; Tiotropium Bromide; Enoxaparin Sodium; Trimethoprim + Sulfamethoxazole; Pantoprazole; Simvastatin; Acetylsalicylic Acid SRT; Ramipril; Acyclovir; Levothyroxine Sodium



Possible Vincristine side effects in 38 year old female

Reported by a physician from United States on 2012-06-01

Patient: 38 year old female

Reactions: Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-13

Mesna
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-13

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Dasatinib
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-13



Possible Vincristine side effects in female

Reported by a physician from Germany on 2012-06-01

Patient: female

Reactions: Syncope, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisolone
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Other drugs received by patient: Nebivolol; Tiotropium Bromide; Acetylsalicylic Acid SRT; Ramipril; Acyclovir; Pantoprazole; Levothyroxine Sodium; Trimethoprim + Sulfamethoxazole; Enoxaparin Natrium; Simvastatin; Torsemide



Possible Vincristine side effects in

Reported by a physician from Germany on 2012-06-01

Patient:

Reactions: Respiratory Disorder, Pain, Myelodysplastic Syndrome, Pyrexia, Neoplasm, Death, Completed Suicide, Thrombocytopenia, Vomiting, Nausea, Anaemia, Acute Myeloid Leukaemia, Toxicity To Various Agents, Haematotoxicity, Hodgkin's Disease, Mucosal Inflammation, Accident, Alopecia, Gastrointestinal Disorder, Nervous System Disorder, non-Hodgkin's Lymphoma, Cardiovascular Disorder, Leukopenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Vincristine
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Indication: Hodgkin's Disease

Prednisone TAB
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Indication: Hodgkin's Disease

Other drugs received by patient: Radiotherapy



Possible Vincristine side effects in

Reported by a individual with unspecified qualification from France on 2012-06-01

Patient:

Reactions: Ejection Fraction Decreased, Febrile Neutropenia, Troponin T Increased, Neutropenia, Thrombocytopenia, Cardiac Failure Congestive, Infection

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Indication: Diffuse Large B-Cell Lymphoma

Pixantrone
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in female

Reported by a physician from Germany on 2012-05-30

Patient: female

Reactions: Syncope, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisolone
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Nebivolol; Trimethoprim + Sulfamethoxazole; Enoxaparin Natrium; Levothyroxine Sodium; Acyclovir; Simvastatin; Torsemide; Tiotropium Bromide; Ramipril; Pantoprazole; Aspirin



Possible Vincristine side effects in 18 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-28

Patient: 18 year old female

Reactions: Oligohydramnios, Normal Newborn, Anaemia, Febrile Neutropenia, Neutropenia, Pregnancy, Thrombocytopenia

Drug(s) suspected as cause:
Neupogen
    Indication: Rhabdomyosarcoma

Dactinomycin
    Dosage: q21d
    Indication: Rhabdomyosarcoma

Vincristine
    Indication: Rhabdomyosarcoma

Cyclophosphamide
    Dosage: 1 df: 2.2g/m2
    Indication: Rhabdomyosarcoma

Mesna
    Indication: Rhabdomyosarcoma



Possible Vincristine side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-28

Patient: female

Reactions: Foetal Growth Restriction, Premature Baby, Anaemia, Thrombocytopenia

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Doxorubicin HCL

Cyclophosphamide

Vincristine

Ifosfamide
    Dosage: 1df= 9g/m3 over 5 days.
    Indication: Ewing's Sarcoma



Possible Vincristine side effects in female

Reported by a physician from Germany on 2012-05-28

Patient: female

Reactions: Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Prednisolone
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Vincristine
    Dosage: 3.94 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Rituximab
    Dosage: 742.5 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Cyclophosphamide
    Dosage: 1483 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Doxorubicin HCL
    Dosage: 100 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Enoxaparin Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Levothyroxine Sodium; Ramipril; Acyclovir; Nebivolol; Simvastatin; Torsemide; Pantoprazole; Acetylsalicylic Acid SRT



Possible Vincristine side effects in female

Reported by a individual with unspecified qualification from United States on 2012-05-25

Patient: female, weighing 14.9 kg (32.8 pounds)

Reactions: Anaemia, Hyponatraemia, Rash, Pyrexia, Ascites, Abdominal Pain Upper, Abdominal Compartment Syndrome, Respiratory Failure, Pneumonia Herpes Viral, Bone Marrow Failure, Neutropenia, Thrombocytopenia, Cardiac Arrest, Septic Shock, Infection in AN Immunocompromised Host

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine
    Dosage: .99 mg

Methotrexate
    Dosage: 24.5 mg

Dexamethasone
    Dosage: 17.5 ml

Mercaptopurine
    Dosage: 460 mg



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-05-08

Patient:

Reactions: Neuropathy Peripheral, Pneumonia, Diabetes Mellitus, Sepsis, Anaemia, Neutropenia, Thrombocytopenia, Disease Progression, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Dexamethasone
    Indication: Multiple Myeloma

Thalomid
    Dosage: 100 milligram
    Administration route: Oral
    Indication: Multiple Myeloma

Bortezomib
    Indication: Multiple Myeloma

Bortezomib

Vincristine
    Indication: Multiple Myeloma

Adriamycin PFS
    Indication: Multiple Myeloma

Other drugs received by patient: Aspirin; Neupogen; Melphalan Hydrochloride



Possible Vincristine side effects in 49 year old female

Reported by a health professional (non-physician/pharmacist) from Taiwan, Province of China on 2012-05-03

Patient: 49 year old female

Reactions: Erythema Infectiosum, Hepatitis Acute, Thrombocytopenia, Leukopenia

Drug(s) suspected as cause:
Epirubicin
    Dosage: 6-cycles
    Indication: Intestinal T-Cell Lymphoma

Cyclophosphamide
    Dosage: 6 cycles
    Indication: Intestinal T-Cell Lymphoma

Vincristine
    Dosage: 6-cycles
    Indication: Intestinal T-Cell Lymphoma

Rituximab
    Indication: Intestinal T-Cell Lymphoma

Dexamethasone
    Dosage: 6-cycles
    Indication: Intestinal T-Cell Lymphoma

Other drugs received by patient: Lamivudine



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from France on 2012-04-26

Patient:

Reactions: Stomatitis, Febrile Neutropenia, Troponin Increased, Ejection Fraction Decreased, Neutropenia, Diffuse Large B-Cell Lymphoma, Thrombocytopenia, Cardiac Failure Congestive, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin HCL

Prednisone TAB

Prednisone TAB

Pixantrone Dimaleate

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab

Vincristine

Prednisone TAB

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB

Prednisone TAB

Rituximab

Cyclophosphamide

Vincristine

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab

Rituximab

Doxorubicin HCL

Cyclophosphamide

Vincristine

Doxorubicin HCL

Cyclophosphamide

Cyclophosphamide

Cyclophosphamide

Vincristine

Rituximab

Cyclophosphamide

Pixantrone Dimaleate

Vincristine

Prednisone TAB

Prednisone TAB

Rituximab

Vincristine

Prednisone TAB
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide

Pixantrone Dimaleate
    Indication: Diffuse Large B-Cell Lymphoma

Pixantrone Dimaleate

Vincristine

Rituximab



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017